

**ANNUAL REPORT
2015**

**Westmead Hospital
Department of Gynaecological
Oncology**

TABLE OF CONTENTS

Report from the Director	4
Overview of Our Service and Team.....	5
Summary of Unit Activity for 2015.....	6
Occasions of service	
In-patient admissions	
Surgery / procedure breakdown	
Multidisciplinary team (MDT) case reviews	
Summary of Activity Trends (2001 – 2015).....	7
Out-patient occasions of service	
Admissions and bed days	
Average length of stay (ALOS)	
Casemix Treated by the Unit	8
Diagnosis of malignancy by site of disease	
Cervical malignancies	
Uterine malignancies	
Ovarian, fallopian tube and primary peritoneal malignancies	
Non-cancer diagnosis	
Morbidity / Mortality Review	10
Sociodemographic Characteristics of Patients	11
Country of birth	
Age distribution	
Body mass index	
Referral base	
Clinical Trials and Studies.....	13
New Grants Awarded.....	17
Multidisciplinary Team Profile	19
Publications.....	24
Conference Presentations / Invited Lectures	26
Chairing / Organising Conference Sessions	28
Consumer and Community Engagement.....	29
Gynaecological Cancer Support Group	
Media and Consumer Forums	
Consumer and Community representation on Research Committees	

REPORT FROM THE DIRECTOR



It is my pleasure to present the 2015 Annual Report for the Department of Gynaecological Oncology which showcases the activities and achievements of the Department. I think you will agree that these are considerable, given the small size of the Department.

During 2015, we saw over 3,000 patients, 642 of which were new patient visits. A total of 476 patients were admitted to the service, 435 of whom had a surgical procedure. The average length of stay for these patients, many of whom had a midline laparotomy, was 3.3 days.

In 2015, we had 13 clinical trials or research studies open for recruitment and recruited 41 patients to these trials and studies. Our trial activity has increased so much that we have added a second full-time trials co-ordinator to our trials team.

In addition to measures of our activity (both clinical and research output), we have included surgical morbidity, length of stay and readmission data which we have collected routinely for many years. Moving forward, we also intend to capture key surgical and oncological performance indicators such as percentage of advanced ovarian cancer patients who had optimal debulking surgery, percentage of patients with laparoscopic adnexal surgery who are day cases, and conversion rates for laparoscopic cases.

One of the hallmarks of this unit (in addition to the provision of high quality care to patients of Western Sydney Local Health District and from elsewhere in the state) is the engagement of most of the members of the unit in high level representation and consultation to the “big picture” of gynaecological cancer care specifically, and also to the psychosocial well-being of the women and their families. This is evidenced by the number of committees, working groups and organisation of conferences that the department members contribute to.

I would like to thank Ms Annie Stenlake for her stellar efforts in assembling this report, and members of the entire team for their outstanding contribution to the department in 2015.

OVERVIEW OF OUR SERVICE AND TEAM

The Department of Gynaecological Oncology is a centralised specialist service, one of 6 designated gynaecological cancer services in the state. It is staffed by a multidisciplinary team of surgeons, nurses, allied health professionals and researchers providing specialist care in the treatment of gynaecological cancers, pre-malignant conditions, suspicious pelvic masses as well as planned and emergency management of benign gynaecological and obstetrical conditions where more complex surgery is required.

Patients have access to the combined radiation / medical oncology service for complex chemotherapy regimens and radiation therapy and/or brachytherapy.

The Department comprises the following cancer specialists and allied health professionals:

Gynaecological Oncologists: A/Prof Alison Brand (Director), Dr Gerard Wain, A/Prof Russell Hogg, Dr Robyn Sayer (locum for 8 weeks)

Clinical Nurse Consultant: Tish Lancaster

Allied Health: Kim Hobbs – Clinical Specialist Social Worker, Suparna Karpe - Clinical Psychologist

Women's Health Ward: Barbara Shaw – Nursing Unit Manager; Evangline Madriaga, Wendy Jessop, and Zahra Anoneuvo – Clinical Nurse Specialists

Data Manager: Annie Stenlake RN, Emerg Nurs Cert, BHSM (Info)

Clinical Trial Co-ordinators: Serene Yoke Wei RN MPH (to Feb 2015), Yuan Guo BMed (China) (from June 2015), Ashika Kumar MBBS (Fiji) MPH (from July 2015), Annie Stenlake (P/T)

Translational Research and Biobanking: Prof Anna deFazio (Head), Catherine Kennedy BSc(Hons), Yoke-Eng Chiew BSc (Hons), Ying Lei PhD, Dashni Srirangan MSc, Catherine Emmanuel PhD (P/T), Jillian Hung MHSc, Jo White RN RM (Oct – Dec), Pamela Provan BAppSci (Hons) MBA, Sarah Potter PhD MPH

The multidisciplinary team maintains a close working relationship with the departments of radiation oncology, medical oncology, tissue pathology and diagnostic oncology, supportive and palliative medicine, cancer genetics and psycho-oncology. These team members are:

Medical Oncology: Prof Paul Harnett, Dr Bo Gao

Radiation Oncology: Dr Viet Do, Dr Jennifer Chard

Tissue Pathology and Diagnostic Oncology: A/Prof Raghwa Sharma, Dr King Tan, Dr Anita Achan, Dr Spinder Samra, Dr Jennifer Kim

Supportive and Palliative Medicine: Dr Phillip Lee

Cancer Genetics: A/Prof Judy Kirk, Dr Kathy Wu

Psycho-oncology: Dr Cathy Mason

SUMMARY OF UNIT ACTIVITY FOR 2015

Out-patient Occasions of Service

The unit provided an average of 13 clinic sessions per fortnight (combined clinics for new and follow-up patient visits).

No. New patient Visits	No. Follow-up Visits	Total Number Clinic Visits
624	2,397	3,021

In-patient Admissions

The unit has two full operating days available each week. All patients, where possible, are admitted to the Women's Health Ward post-operatively, unless planned for admission to a High Dependency Unit.

No. Surgical Admissions (benign)	No. Surgical Admissions (malignant)	No. Medical Admissions	Total Number Admissions	Average Length of Stay (ALOS)
145	290	41	476	3.3 days

Surgery / Procedure Breakdown

Laparoscopic procedures, other than for diagnostic purposes, have been included in the 'major surgery' category.

No. Minor Procedures	No. Major Procedures	Total Number Procedures
141	294	435


Multidisciplinary Team (MDT) Case Reviews

No. Diagnostic Reviews (eg. curette/bx)	No. Reviews for Definitive Management Plan	No. PET Scans or General Discussion Reviews (no path)	No. Cases Written Up *	No. Cases Discussed *
284	435	33	752	707


Note: H+E slides may have been requested from and outside laboratory and did not arrive in time for a meeting, or a case may not have completed in time for a meeting, thus the difference between numbers of cases written up and discussed (marked *)

SUMMARY OF ACTIVITY TRENDS (2001- 2015)


Outpatient Occasions of Service



Admissions and Bed Days



Average Length of Stay (ALOS)



CASEMIX TREATED BY THE UNIT

Diagnosis of Malignancy by Site of Disease

Patients with a diagnosis of malignancy (excluding LMP tumours) accounted for 48% of cases treated by the Unit. When including LMP tumours, it is 51%.

Cancer site	No. cancer cases	% of all cancer cases
Cervix	50	16
Uterus	141	45
Ovary / Fallopian Tube / Peritoneum	83	27
Vulva / Vagina	13	4
Gestational Trophoblastic Disease	5	2
Other (eg. primary GIT, metastatic breast)	20	6
Total	312	

Cervical malignancies

Stage of Disease	No. cases	% of all cervical malignancies
I	28	56
II	13	26
III	7	14
IV	2	4

Uterine malignancies

Stage of Disease	No. cases	% of all uterine malignancies
I	95	67
II	12	9
III	12	9
IV	14	10
Unstaged	8	6

Ovarian, fallopian tube and primary peritoneal malignancies

Stage of Disease	No. cases	% of all adnexal malignancies
I	23	28
II	7	8
III	27	33
IV	15	18
Unstaged	11	13

Non-cancer Diagnosis

Patients with a non-cancer diagnosis accounted for 52% of cases treated by the Unit.

Site of Disease	No. non-cancer cases	% of all non-cancer cases
LMP tumours	21	6
High grade dysplasia or CAH	51	15
Benign or low grade dysplasia	225	67
Prophylactic	38	11
Unknown / no diagnosis confirmed	1	< 1
Total	336	

Note: Not all cases seen in the prophylactic group above will necessarily have had risk-reducing surgery.

MORBIDITY / MORTALITY REVIEW

The Gynaecological Oncology Unit presents its morbidity / mortality cases on a biennial basis at the weekly Divisional meeting. Currently the Unit uses the RANZCOG Gynaecological Oncology Sub-speciality Practice Improvement Critical Event (GOSPICE) criteria, though it is acknowledged that these are somewhat out-dated and need to be reviewed.

For the 12 month period in 2015 there were a total of 53 events recorded in 45 patients, out of a total of 476 admissions.

Critical Event	No. events	
Unplanned return to operating theatre	3	0.6%
Death within 30 days of surgery	1	0.2%
Post-operative fistula	1	0.2%
Intra-operative haemorrhage requiring > 6 unit blood transfusion	0	0
Unplanned transfer to Intensive Care Unit	4	0.8%
Post-operative stay > 21 days	2	0.4%
Hospital acquired infection after 5 th post-operative day	4	0.8%
Post-operative pulmonary embolus	2	0.4%
Anastomotic leak after bowel surgery	1	0.2%
Unplanned readmission within 30 days	21	4.4%
Other	9	1.9%

'Other' critical events included bowel injury (2), bladder injury (1), cardiac events [eg. new onset atrial fibrillation, myocardial infarct] (5), and dural puncture (1),

SOCIODEMOGRAPHIC CHARACTERISTICS OF OUR PATIENTS

Country of Birth

Only 57% of patients were born in Australia, although 66% were born in either Australia or another English-speaking country (see marked *). Note: information not available for 5 patients

Country of Birth	No. Patients	Country of Birth	No. Patients	Country of Birth	No. Patients
Afghanistan	3	India	18	Samoa	4
Argentina	1	Indonesia	4	Scotland *	3
Armenia	1	Iran	2	Serbia	2
Aruba	1	Iraq	2	Singapore	1
Australia *	364	Ireland*	3	Somalia	1
Austria	1	Italy	7	South Africa *	3
Bosnia	1	Jordan	2	Sri Lanka	9
Cambodia	1	Korea	1	Sudan	1
Canada*	1	Lebanon	13	Switzerland	3
China	32	Malaysia	4	Syria	2
Croatia	5	Malta	7	Taiwan	1
Cyprus	1	Myanmar	2	Thailand	1
Egypt	2	Nepal	1	Tonga	3
England *	25	Netherlands	2	Turkey	3
Ethiopia	1	New Zealand *	24	Ukraine	1
Fiji	7	Nigeria	1	United States *	3
Finland	3	Pakistan	2	Uruguay	1
France	2	Peru	1	Vietnam	5
Germany	7	Philippines	27	Wales *	1
Greece	3	Poland	3	Yugoslavia	2
Hong Kong	3	Russia	2		

Age Distribution

Age Range (years)	No. Patients	%
< 20	3	< 1
20-29	30	5
30-39	60	10
40-49	137	21
50-59	142	22
60-69	137	21
70-79	99	15
80-89	38	6
90-99	2	<1

Body Mass Index (BMI)

Normal range 20-25 Overweight > 25 – 30

Morbidly obese > 30

BMI	%	%	%
< 20	4		
20-25	27		
>25 - 30	24	69	
>30 - 35	19		45
>35 – 40	13		
>40 – 50	10		
>50 - 60	2		
>60	<1		

Referral Base

The majority of patients (71%) are referred to the unit from within either Western Sydney LHD or the adjacent Nepean Blue Mountains LHD. Rural referrals (including Illawarra and Central Coast LHD) account for 19% of patients, with close to half of these being referred from Western NSW LHD.

Local Health District (LHD)	No. Patients	%
Western Sydney LHD	285	44
Nepean Blue Mountains LHD	171	27
South Western Sydney LHD	40	6
Northern Sydney LHD	19	3
Sydney LHD	5	<1
South Eastern Sydney LHD	0	0
Illawarra Shoalhaven LHD	23	4
Central Coast LHD	5	<1
Western NSW LHD	48	7
Murrumbidgee LHD	27	4
Southern NSW LHD	11	2
Hunter New England LHD	6	1
Mid North Coast LHD	0	0
Northern NSW LHD	0	0
Far West LHD	0	0
Interstate / overseas	3	<1

CLINICAL TRIALS AND STUDIES

The Department of Gynaecological Oncology conducts a numbers of clinical trials exploring better treatment options for patients with a gynaecological cancer. The unit participates in a number of phase II and III trials and maintains a balance of trials sponsored by Pharmaceutical companies and not-for-profit organisations through a strong association with the collaborative clinical research group, Australia and New Zealand Gynaecological Oncology Group (ANZGOG). ANZGOG is the peak clinical trials research group for gynaecological cancers in Australia and New Zealand

Additionally, the Department has a strong translational research and basic science research group. Laboratory research is carried out in the Westmead Institute for Medical Research. We are affiliated with the University of Sydney and are members of the Sydney West Translational Cancer Research Centre, striving to rapidly translate our research findings into new tests and treatments that will eventually be of direct benefit to our patients.

Westmead Department of Gynaecological Oncology clinical trials and research studies involve research in ovarian cancer, cervical cancer, and cancer of the uterus, vulva and vagina.

Name	Trial / Research Study / Audit	Local PI(s)	Status	No. patients recruited in 2015
SUPER Solving Unknown Primary Cancer	Research Study	Prof Anna deFazio	Open to recruitment	12
OUTBACK Phase 3 trial of adjuvant chemo following chemo radiation as primary treatment for locally advanced cervix cancer compared to chemo-radiation alone	Trial	Dr Viet Do	Open to recruitment	1
WHAM Impact of risk-reducing BSO on non-cancer outcomes in young high-risk women	Trial	A/Prof Judy Kirk A/Prof Alison Brand	Open to recruitment	3
PARAGON Phase 2 study of Anastrozole in women with potentially hormone sensitive recurrent / metastatic gynaecological cancer	Trial	A/Prof Alison Brand	Open to recruitment	0
Sentinel Node Audit Prospective audit of sentinel node biopsy for vulvar carcinoma in Australia and New Zealand	Audit	A/Prof Alison Brand	Open to recruitment	1

Name (cont'd)	Trial / Research Study / Audit	Local PI(s)	Status	No. patients recruited in 2015
Vaginal Oestriol A phase 2 study of the use of vaginal oestriol to prevent vaginal stenosis in patients treated with pelvic radiotherapy for gynaecological, rectal and anal malignancies	Trial	A/Prof Alison Brand	Open to recruitment	4
ARIEL 2 Extension Study A phase 2 study of Rucaparib in patients with platinum-sensitive relapsed high grade serous ovarian cancer to characterise the relationship between efficacy and homologous recombination repair deficiency	Trial	Prof Paul Harnett	Open to recruitment	0
REZOLVE A phase 2 study to evaluate the safety and potential palliative benefit of intra-peritoneal Bevacizumab in patients with symptomatic ascites due to advanced chemotherapy-resistant ovarian cancer	Trial	Prof Paul Harnett	Open to recruitment	0
A phase 1A/1B, open label, multiple-dose, dose escalation and expansion study to investigate the safety and pharmacokinetics of the B-RAF inhibitor BGB-283 in subjects with solid tumours	Trial	Dr Adnan Nagrial Dr Bo Gao	Open to recruitment	2
A phase 1/2A dose escalation and cohort expansion study for safety, tolerability and efficacy of anti-GITR monoclonal antibody (BMS-936558, anti PD-1 monoclonal antibody) in advanced solid tumours	Trial	Dr Matteo Carlino	Open to recruitment	1
Determining sleep phenotypes in cancer cohorts: interactions with cancer biology and impacts on quality of life	Research study	Dr Gerard Wain Prof Anna deFazio	Open to recruitment	12

Name (cont'd)	Trial / Research Study / Audit	Local PI(s)	Status	No. patients recruited in 2015
OPAL Improving outcomes from ovarian cancer: building the evidence to help women help themselves	Research study	Dr Gerard Wain	Open to recruitment to March 2015 only	3
MILO A multi-national, randomized, open-label phase 3 study of MEK162 versus physician's choice of chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube or primary peritoneum	Trial	Prof Paul Harnett	Open to recruitment but study discontinued at interim analysis	2
Rekindle Testing an on-line resource to promote sexual well-being for both cancer patients and their partners	Research study	Kim Hobbs (AI)	Open to recruitment	N/A On-line resource
Social work interventions in cancer care: a national, multicentre QA study using clinical data mining methodology	Quality assurance study	Kim Hobbs	Not recruiting at Westmead	N/A
Health literacy among adult patients of allied health at Westmead Hospital: an observational, survey-based study	Research study	Kim Hobbs	HREC Approval Dec 2015	0
Meki 12 Phase 2 randomised, double-blind trial of combination of Pimasertib with SAR245409 or of Pimasertib with SAR245409 placebo in subjects with previously treated unresectable low grade ovarian cancer	Trial	Prof Paul Harnett	Closed to recruitment 3 patients in follow-up	N/A
PORTEC 3 Randomised phase 3 trial comparing concurrent chemo-radiation and adjuvant chemotherapy with pelvic radiation alone in high-risk and advanced stage endometrial carcinoma	Trial	Dr Gerard Wain	Closed to recruitment 15 patients in follow-up	N/A

Name (cont'd)	Trial / Research Study / Audit	Local PI(s)	Status	No. patients recruited in 2015
ICON 8 An international phase 3 randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer	Trial	A/Prof Alison Brand	Closed to recruitment 9 patients in follow-up	N/A
AOCS Australian Ovarian Cancer Study	Research study	Dr Gerard Wain	Closed to recruitment 11 patients in follow up	N/A

NEW GRANTS AWARDED

Funding Source	Title	Investigators	Amount and Grant Period
Cancer Australia	ICON 9 A phase 3 randomised trial of cediranib and olaparib maintenance in patients with relapsed platinum sensitive ovarian cancer.	Brand A, CI (B) Mileshkin L Ledermann J Rischin D Beale P Quinn M Coward J Viney R Martyn J	\$600,000 2016 - 2019
Cancer Council NSW RG-15-23	Novel treatment targets in low-grade serous ovarian cancer	deFazio A Bowtell D Harnett P Balleine R Rizos H	\$358,715 2015 – 2017
Cancer Australia APP1082604	RECUPERATE: Can REaltime molecular profiling in Carcinoma of Unknown Primary improvE tReAtment ouTcomes?	Mileshkin L Bowtell D Schofield P Karapetis C deFazio A Tattersall M	\$599,602 2015 - 2017
Cancer Institute NSW 14/TPG/1-15	INOVAte Individualised ovarian cancer treatment through integration of genomic pathology into multidisciplinary care	CIs deFazio A Harnett P Friedlander M Balleine R Bowtell D Samimi G Wain G Hacker N Marsh D Beale P AIs McDonald D Brand A Fulcher D Sharma R Anderson L Gao B Gard G Valmadre S Baron-Hay S Hogg R Maidens J Harris A Lazarus S Sengupta S	\$3,746,690 2015 - 2020

Funding Source	Title	Investigators	Amount and Grant Period
Cancer Institute NSW 15/REG/1-19	Standardised genome analyses for every cancer researcher in NSW	Dinger M Marshall G McDonald K Moscazto P Thomas D DeFazio A	\$495,000 2015
Cancer Institute NSW 15/REG/1-14	Covaris evolution adaptive focused acoustic ultrasonicator for enhancement of cancer research within the Sydney West Hub	Graham D Clarke C DeFazio A George J Liddle C Booth D	\$70,762 2015
Sydney West TCRC Partner Program (CINSW)	Genomic pathology, tumour biomarkers and circulating tumour DNA: Optimising management of melanoma and ovarian cancer	DeFazio A Mann G	\$150,000 2015 – 2016
Cancer SPARC Implementation Scheme, University of Sydney	Determining sleep phenotypes in cancer cohorts: Interactions with cancer biology and impacts on quality of life	Kairaitis K Amis T Mann G DeFazio A Wain G Clarke C Dhillon H Marshall N	\$155,438 2015 - 2016
Cancer Institute NSW 15/RIG/1-16	Next-generation cancer biobanking: Adding value to the SW-TCRC Gynaecological Oncology Biobank at Westmead	DeFazio A	\$288,812 2015 - 2016
		Total	\$6,465,018

MULTIDISCIPLINARY TEAM PROFILE

Gynaecological Oncologists

Associate Professor Alison Brand (Director)

MD, MMed, FRCS(C), FRANZCOG, CGO

Professional Memberships

Australia and New Zealand Gynaecological Oncology Group (ANZGOG)
Clinical Oncology Society of Australia (COSA)
Australian Society of Gynaecologic Oncologists (ASGO)
Australian Medical Association (AMA)
Fellow, Royal Australian and New Zealand College of Obstetricians and Gynaecologists
International Gynecologic Cancer Society (IGCS)
Gynaecologic Oncologists of Canada (GOC)
Fellow, Royal College of Physicians and Surgeons of Canada (RCPSC)
Society of Obstetricians and Gynaecologists of Canada (SOGC)

Committee Appointments

Australia and New Zealand Gynaecologic Oncology Group (ANZGOG) Clinical Trials
Group: Chair, ANZGOG
Director, ANZGOG
Member, Research Advisory Committee
Member, Quality Assurance Committee
Member, Nominations Committee
ANZGOG representative, GCIG Board of Directors
Examiner, Certification in Gynaecological Oncology, RANZCOG
Cancer Australia, Gynaecological Cancer Advisory Group
Cancer Council Australia, Working Party for the Development of Clinical Management
Guidelines for the Prevention of Cervical Cancer
Clinical Oncology Society of Australia (COSA), Council
Senior Editor, International Journal of Gynaecological Cancer
Gynaecological Oncology Biobank at Westmead Management Committee

Research Supervision

R Mohan: Concordance of endometrial sampling with final histology in endometrial cancer

S Kapurubandara: Opportunistic salpingectomy during surgery for benign disease: A survey of Australian practice

A Thiru: Evaluation of extended VTE prophylaxis in gynaecological cancer patients

D Thangavel: Patient satisfaction in enhanced recovery gynaecological oncology surgery

S Kapurubandara: Retrospective review of fast track versus usual care in general gynaecological surgery

Dr Gerard Wain
MBBS, FRANZCOG, CGO

Professional Memberships

Fellow, Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG)
Australia & New Zealand Gynaecologic Oncology Group (ANZGOG) Clinical Trials Group
International Gynecologic Cancer Society (IGCS)
Australian Society of Gynaecologic Oncologists (ASGO)

Committee Appointments

Associate Editor, Australian and New Zealand Journal of Obstetrics and Gynaecology

Associate Professor Russell Hogg
MBBS, PhD, FRANZCOG, CGO

Professional Memberships

Fellow, Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG)
Australia & New Zealand Gynaecologic Oncology Group (ANZGOG) Clinical Trials Group
International Gynecological Cancer Society (IGCS)
European Society for Gynaecological Cancer (ESGC)
Australian Society of Gynaecologic Oncologists (ASGO)

Committee Appointments

Co-chair and member, Gynaecological Oncology Network Executive Committee - Agency for Clinical Innovation (ACI)
Cancer Institute NSW, Skilled Professionals Advisory Committee
Royal Australian and New Zealand College of Obstetricians and Gynaecologists
 Supervisor, Registrar Training
 Committee Assessor, Registrar Research
Reviewer, Journal of the International Gynecologic Cancer Society

Dr Robyn Sayer
Locum (0.6 FTE) 4/8/2015 – 9/10/2015 to cover staff long-service leave
MD, FACOG, FRANZCOG

Translational Research and Bio-banking

Prof Anna deFazio

Sydney West Chair of Translational Cancer Research, Centre for Cancer Research
BSc, PhD

Committee Appointments

Australian Gynaecological Cancer Foundation, Scientific Advisory Committee
Australian Ovarian Cancer Study
 Management Committee
 Access Committee
Cancer Council NSW, Research Committee
Cancer Institute NSW, Biospecimen Stakeholder Network
CellBank Australia, Scientific Advisory Committee
kConFab (Kathleen Cuninghame Consortium into Familial Breast Cancer)
 Chair, Biospecimen Committee
 Executive Committee
National Health and Medical Research Council Assigners Academy, Project Grants
University of Sydney
 Cancer SPARC Steering Committee
 Research Advisory Group (convened by Deputy Vice-Chancellor (Research))
Westmead Institute for Medical Research Faculty
Sydney-West Translational Cancer Research Centre, Executive Committee
Gynaecological Oncology Biobank at Westmead
 Management Committee
 Access Committee

PhD Supervision

Dr Bo Gao MBBS, MSc, FRACP
University of Sydney (Supervisor, Prof Anna deFazio, co-supervisors Prof Paul Harnett and
A/Prof Rosemary Balleine)
Genetic polymorphisms and chemotherapy response in ovarian cancer
PhD awarded 10 Dec, 2015

Dr Cristina Mapagu - PhD candidate MMedSc, MBBS (Hons), FRACP

Dr Tania Moujaber - PhD candidate MMedSc, MBBS (Hons), FRACP

Nursing and Allied Health

Letitia Lancaster

Clinical Nurse Consultant
BScN, Oncology Cert, FACN

Professional Memberships

Clinical Oncology Society of Australia (COSA)
Cancer Nurses Society of Australia (CNSA)
Gynaecological Oncology Nurses Group (GONG)

Committee Appointments

International Nurses in Cancer Care
 Nominations and Award Committee
 Membership Committee
 Knowledge and Dissemination Committee
Co-editor, Australian Journal of Cancer Nursing
Editorial Board, Cancer Forum Journal
Reviewer, International Journal of Gynecologic Cancer
Cancer Australia
 National Centre for Gynaecological Cancer Advisory Group
 'Supporting women to live well with gynaecological cancer, Project Working Group
 'Endometrial cancer shared follow-up care, Project Working Group
Westmead Hospital
 Clinical Board
 Safety in Medicine Committee
 Nursing and Midwifery Quality Council
 Panel interviewer, Graduate Nurses Transition to Practice

Kim Hobbs

Specialist Clinical Social Worker
BSocStuds (Hons), MSW

Professional Memberships

Clinical Oncology Society of Australia (COSA)
Oncology Social Work Australia (OSWA)
NSW Social Workers Oncology Group (SWOGO)
Psycho-Oncology Co-operative Research Group (PoCoG)
Honorary Associate, Faculty of Health, University of Technology Sydney

Committee Appointments

Australian Association of Social Workers, National Research Committee
OSWA representative COSA Council
OSWA Executive Committee
PoCoG Scientific Advisory Committee
Department of Health and Cancer Australia, Cervical Cancer Screening Guidelines Working Party
Allied Health representative, Gynaecological Oncology Nurses Group
Co-chair and member, Gynaecological Oncology Network Executive Committee - Agency for Clinical Innovation (ACI)
Social Work representative, Sydney West LHD Allied and Community Health Research Steering Committee

Suparna Karpe

Clinical Psychologist
MA (Clinical Psychology) MPhil (Clinical Psychology)

Professional Memberships

Australian Psychological Society (APS)
Psycho-Oncology Co-operative Research Group (PoCoG)
Australia and New Zealand Association for Contextual Behavioural Science (ACBS)
Agency for Clinical Innovation (ACI)
Australia & New Zealand Gynaecologic Oncology Group (ANZGOG)

PUBLICATIONS

- Kapurubandara S, Qin V, Gurrum D, Anpalangan A, Merkur H, Hogg R, Brand A. Opportunistic bilateral salpingectomy during gynaecological surgery for benign disease: A survey of current Australian practice. *Aust N Z J Obstet Gynaecol* .2015 Dec 7;55(6)606-11Epub 2015 Sept 7
- Webb PM, deFazio A, Protani MM, Ibiebele TI, Nagle CM, Brand AH, Blomfield PI, Grant P, Perrin LC, Neale RE, for the Australian Ovarian Cancer Study Group. Circulating 25-hydroxyvitamin D and survival in women with ovarian cancer. *Am J Clin Nutr*. 2015; 102(1):109-114
- Brand A, Harrison A, Kumar K. "It was definitely very different": An evaluation of palliative care teaching to medical students using a mixed methods approach. *Journal of Palliative Care*. 2015; 31(1):21-8
- Brand A. Jack of all trades, master of none? The need for centralisation services for rarely performed procedures (Letter). *Aust N Z J Obstet Gynaecol*. 2015; 55(3):298
- Beesley V, Rowlands I, Hayes S, Janda M, O'Rourke M, Marquant L, Quinn M, Spurdle A, Obermair A, Brand A, Oehler M, Leung Y, McQuire L, Webb P on behalf of the Australian Endometrial Cancer Study Group. Incidence, risk factors and estimates of a woman's risk of developing secondary lower limb lymphedema and lymphedema-specific supportive care needs in woman treated for endometrial cancer. *Gynecol Oncol*. 2015; 136(1):87-93
- Candido Dos Reis FJ, Song H, Goode EL, ... deFazio A, ... Pharoah PD. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. *Clinical Cancer Res*. 2015; 21: 652-7
- Lei Y, Henderson BR, Emmanuel C, Harnett PR, deFazio A. Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis. *Oncogene*. 2015; 34: 485 - 95
- Nagle CM, Ibiebele TI, deFazio A, Protani MM, Webb PM, on behalf of the Australian Ovarian Cancer Study Group. Aspirin, non-aspirin, non-steroidal anti-inflammatory drugs, acetaminophen and ovarian cancer survival. *Cancer Epidemiol*..2015; 39:196-9
- Patch A, Christie E, Etemadmoghadam D, ... The Australian Ovarian Cancer Study Group, Hamilton A, Mileskin L, Au-Yeung G, Kennedy C, Hung J, Chiew Y-E, Harnett P, ... deFazio A, Grimmond S, Bowtell D. Whole genome characterisation of chemo-resistant ovarian cancer. *Nature*. 2015; 521(7553):489-94
- Tembe V, Martino-Echarri E, Marzec KA, Mok MT, Akhurst KM, Mills K, Lei Y, deFazio A, Rizos H, Kettle E, Boadle R, Henderson BR. The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function. *Cell Signal*. 2015; 27:1763-1771
- Nagle CM, Dixon SC, Jensen A, Kjaer SK, Modugno F, deFazio A, Fereday S, Hung J, Johnatty SE, Australian Ovarian Cancer Study Group, ... Webb PM. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. *Br J Cancer*. 2015; 113: 817-26
- Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, Consortium of Modifiers of BRCA, Hollestelle A, van der Baan FH, Berchuck A, ... deFazio A, ... Pharoah PDP, Rookus MA, Hooning MJ, and Goode EL. No clinical utility of KRAS variant rs61764370 for breast or ovarian cancer. *Gynecol Oncol*. 2015 May 2 [Epub ahead of print]

Johnatty S, Tyrer JP, Kar SP, Beesley J, Lu Y, Gao B, ... Kennedy C, Chiew YE, Berchuck A, Macgregor S, Pharoah P, Goode EL, deFazio A, Webb P, Chenevix-Trench G. Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium. *Clin Cancer Res*. 2015; 21:5264-76

Hunter SM, Anglesio MS, Ryland GL, Sharma R, Chiew YE, Rowley SM, Doyle MA, Li J, Gilks CB, Moss P, Allan PE, Stephens AN, Huntsman DG, deFazio A, Bowtell DD, Australian Ovarian Cancer Study G, Gorringer KL, Campbell IG. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. *Oncotarget*. 2015; 6:37663-77

Robinson T, Janssen A, Kirk J, deFazio A, Goodwin A, Tucker K, Shaw T. New approaches to continuing medical education: a QStream (spaced education) program for research translation in ovarian cancer. *J Cancer Educ*. 2015; (epub ahead of print 5 Nov 2015)

Pockett R, Dzidowska M, Hobbs K. Social work intervention research with adult cancer patients: A literature review and reflection on knowledge-building for practice. *Social Work in Health Care*. 2015; 54: 582-614

Lawsin C, Butow P, Miller A, Kay J, McGeechan K, Juraskova I, Boyle F, Ritterband L, Hobbs K, Lambert S, Brotto L, Beaumont A. Improving reach and uptake of psychosexual support: introducing Rekindle, a web-based psychosexual resource for all cancer survivors and their partners. *Psycho-Oncology* .July 2015; 24:38-39

Zordan R, Butow P, Kirsten L, Charles M, Hobbs K, Batterby E, Friedsam J, O'Reilly A, Juraskova I. Supporting the supporters: A randomized controlled trial of interventions to assist the leaders of cancer support groups. *Journal of Community Psychology* 2015; 43(3): DOI:10.1002/jcop.21677

Lancaster L. Much to celebrate, but we need to do more (Editorial). *Australian Journal of Cancer Nursing*, 2015; 16(1):2-3

CONFERENCE PRESENTATIONS / INVITED LECTURES

deFazio A. *INOVAte - Individualised Ovarian Cancer Treatment Through Integration of Genomic Pathology into Multidisciplinary Care.* The Crown Princess Mary Cancer Centre Symposium 20 November 2015 **(INVITED)**

Karpe S. Mindfulness for clinicians. The Crown Princess Mary Cancer Centre Symposium 20 November 2015 **(INVITED)**

deFazio A. 'Gynaecological Cancer Research'. Gynaecological Cancer Patient Support Group, Westmead Hospital, Sydney, 13 November 2015 **(INVITED)**

deFazio A. *Single nucleotide polymorphism, drug clearance and survival in ovarian cancer* 14th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Rotterdam, The Netherlands. October 11-15, 2015 **(INVITED)**

deFazio A., Moujaber T., Etemadmoghadam D, Kennedy C., Balleine R, Saunders C, Wain G., Dobrovic A, AOCS Group, Bowtell D, Harnett P. *BRAFV600E mutations in ovarian cancer and response to the BRAF inhibitor, dabrafenib* American Association for Cancer Research Special Conference On Ovarian Cancer; Orlando, Florida; 2015

deFazio A. *Ovarian cancer & treatment.* Westmead Research Hub Student Open Day, 18 September 2015 **(INVITED)**

de Fazio A. *Genomic and genetic determinants of treatment response and clinical outcome in epithelial ovarian cancer.* 11th Indo-Australian Biotechnology Conference, Sydney, Australia, 7-8 September, 2015 **(INVITED)**

deFazio A. *Essential clinical annotation for NSW Biobanks through data integration using State and Commonwealth datasets.* Biobanking Stakeholder Network Symposium, University of Sydney, 22 May 2015 **(INVITED)**

deFazio A *Latest scientific trends in gynaecological cancers* NSW Agency for Clinical Innovation. Gynaecological Oncology Nurses & Allied Health Group (GONG). Royal Prince Alfred Hospital. 15 May, 2015 **(INVITED)**

deFazio A *Clinico-genomics of ovarian cancer - Identifying mechanisms of resistance and treatment response.* Westmead Millennium Institute Seminar Series, 7 May, 2015 **(INVITED)**

deFazio A. *The increasing role of the translational scientist in the treatment of gynaecological cancers (Tissue Banking).* Royal College of Obstetricians and Gynaecologists World Congress. Brisbane Australia, 12 – 15 April 2015 **(INVITED)**

Ryland G, Hunter S, Christie M, Doyle M, Caramia F, Li J, Rowley S, Allan P, Hadley A, Stephens A, Wakefield M, Antill Y, Ananda S, Mitchell C, Bae S, Lipton L, Boussioutas A, M F, Liauw W, Fox S, de Fazio A., Bowtell D, AOCS, Pyman J, Scott C, Campbell I, Gorringer K. *Genomic analysis of mucinous tumours.* ANZGOG; Gold Coast; 2015

French J, Johnatty S, Lu Y, Beesley J, Gao B., de Fazio A., Edwards L, Macgregor S, Chenevix-Trench G, on behalf of the Ovarian Cancer Association Consortium. *Genome-wide association study identifies PSIP1 associated with progression-free survival in epithelial ovarian cancer.* ANZGOG. Gold Coast, Qld; 2015

Dickson K, Cole A, Kennedy C, Clarkson A, Gard G, Chou A, Gill A, Clifton-Bligh R, deFazio A, Marsh D. *Epigenetics informing future treatment strategies for high grade serous ovarian cancer – looking to histones, ubiquitin and chromatin relaxation*. Third Lowy Cancer Symposium 'Drug discovery to Personalised Medicine' Coogee, NSW; 2015

Irvine K, Nair P, Potter S, DeFazio A. *Longitudinal data linkage: Can it minimise manual patient follow up for NSW Biobanks?* Australian Clinical Trials Alliance (ACTA) 2015 International Clinical Trials Symposium. Sydney, Australia; 2015

Kennedy C, Chiew Y-E, Hung J, Sharma R, Balleine R, Achan A, Stenlake A, Wain G, Brand A, Hogg R, Harnett P, deFazio A. *GynBiobank at Westmead: Making the most of what we've got*. Australasian Biospecimen Network Association Annual Scientific Meeting. Coogee, Sydney; 2015

Mapagu C, Fereday S, Australian Ovarian Cancer Study Group, Bowtell D, Harnett P, deFazio A. *Patterns of use and clinical benefit of endocrine therapy in women with epithelial ovarian cancer*. Postgraduate Cancer Research Network 2015; University of Sydney, Sydney; 2015 (**ORAL PRIZE**)

Mapagu C, Fereday S, Australian Ovarian Cancer Study Group, Bowtell D, Harnett P, deFazio A. *Endocrine therapy for ovarian cancer in the Australian Ovarian Cancer Study (AOCS)*. The Westmead Association Hospital Week 2015 Research Symposium. Westmead, NSW; 2015

Moujaber T, Etemadmoghadam D, Kennedy C, Balleine R, Saunders C, Wain G, Dobrovic A, Australian Ovarian Cancer Study Group, Bowtell D, Harnett P, deFazio A. *BRAF mutations and response to BRAF inhibition in epithelial ovarian cancer*. Postgraduate Cancer Research Symposium 2015; University of Sydney, Sydney; 2015 (**ORAL PRIZE**)

Moujaber T, D E, Kennedy C, Balleine R, Saunders C, Wain G, Dobrovic A, Australian Ovarian Cancer Study Group, Bowtell D, Harnett P, deFazio A. *BRAF mutations and response to BRAF inhibition in epithelial ovarian cancer*. CPMCC Symposium 2015; Sydney Olympic Park, Sydney; 2015 (**Selected for oral presentation**)

Moujaber T, Etemadmoghadam D, Kennedy C, Balleine R, Saunders C, Bowtell D, Harnett P, deFazio A. *Response to dabrafenib in a patient with BRAFV600E mutation positive, low-grade serous ovarian cancer*. Westmead Hospital Week Research Symposium 2015; Westmead, NSW; 2015 (**POSTER PRIZE**)

Yip,S; Hague,W, Price T, Mitchell, P, Davis; ID, Brand, A, Rosenthal, M, Simes, RJ, Stockler MR. *Pursuing biospecimens –translational research in investigator-initiated clinical trials in oncology*. Australian Clinical Trial Alliance Scientific Meeting. Sydney Australia, 8-9 October 2015

Hobbs K, *Cancer in pregnancy: to terminate or not to terminate?* Invited Speaker at 'Rare Cancers: Common Goals', 42nd Annual Scientific Meeting of Clinical Oncological Society of Australia (COSA), Hobart, November 2015

Hocking A, Hobbs K, Pockett R *Lessons in developing a national collaborative research agenda in oncology social work*. Poster presentation at 11th National Allied Health Conference, Melbourne, November 2015

Hobbs K, *Developing skills for psychosexual assessment and intervention in the context of cancer*, Invited Speaker, 'Critical Conversations: Sex, Death and Taxes', 10th Oncology Social Work Australia (OSWA) National Conference, Sydney, September 2015

Hobbs K, Hocking A, Joubert L, Pockett R. *Defining an oncology social work research agenda: a collaborative approach*. Presented at 'Critical Conversations: Sex Death and Taxes', 10th Oncology Social Work Australia (OSWA) National Conference, Sydney, September 2015

Hobbs K, *Psychosexual assessment in the context of chronic illness*. Presented at Royal Prince Alfred Hospital Social Work Symposium, Sydney, May 2015

Lancaster L. *The use of vaginal dilators after brachytherapy and radiotherapy for gynaecological cancer*. Australian Brachytherapy Conference, Sydney 2015 (invited)

Lancaster L. *Writing for publication*. Education evening, NSW Division of Australian Association of Stomal Therapy Nurses, Sydney 2015

CHAIRING / ORGANISING CONFERENCE SESSIONS

Alison Brand, Organiser, ANZGOG Annual Scientific Meeting (May 2015), Gold Coast, QLD

Anna deFazio, Session Chair, 11th Indo-Australian Biotechnology Conference, Sydney, Australia, 7-8 September 2015

Anna deFazio, Session Chair, Westmead Research Hub Student Open Day, 18 September 2015. Infectious disease, immunology and cancer

Anna deFazio, Session Chair, 14th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, 11-15 October 2015, Rotterdam, The Netherlands.

Anna deFazio, Organising Committee, Crown Princess Mary Cancer Centre Symposium, November 2015

Anna deFazio, Management Committee, Westmead Hospital - Hospital Week Research Symposium, August 2015

Letitia Lancaster. Abstract reviewer, Cancer Nurses Society of Australia 18th Winter Congress, 2015

Letitia Lancaster, Co-convenor, NSW Agency for Clinical Innovation, Gynaecological Oncology Nurses Study Day, 2015

CONSUMER AND COMMUNITY ENGAGEMENT

Gynaecological Cancer Support Group

Support groups are held monthly and are convened by Kim Hobbs (Social Worker) and Suparna Karpe (Clinical Psychologist). These are free and open to all patients who have been diagnosed with a gynaecological cancer, regardless of where they are receiving care. Guest speakers are invited to the meeting and topics cover a wide range of issues from cancer research updates, cancer genetics, coping with cancer, natural therapies, access to community services, and entitlements to statutory benefits. Following the presentations by guest speakers, there is an opportunity to ask questions and meet others over morning or afternoon tea. This also provides an opportunity for the sharing of support and experiences.

Narelle Holden (Westmead Hospital Aboriginal Liaison Officer) also runs a Support Group for Indigenous patients with a cancer diagnosis.

Media and Consumer Forums

Alison Brand, October 2015. ANZGOG video: *Taking part in a clinical trial*.
<http://www.goforgynae.org.au/research/>

Alison Brand, September 27, 2015. ABC TV Breakfast. *Gynaecological cancer awareness and "Go for Gynae" ANZGOG fundraising initiative*

Alison Brand, February 28, 2015: Ovarian Cancer Australia Resilience Consumer Forum. *"Clinical Trials and New Treatments: Partners in progress"*. Sydney.

Consumer and Community Representation on Research Committees

We are very grateful for the time and effort the following people have afforded, not only to our local Westmead gynaecological oncology research unit, but also our larger peak gynaecological oncology research body.

Westmead Translational Research and Bio-banking

Alison Harris
Sapna Lazarus

Australia and New Zealand Gynaecological Oncology Group (ANZGOG)

Cheryl Waller
Rhonda Beach

Both are members of the Consumer and Community Committee (CCC) and the Research Advisory Committee (RAC)